Skip to main content

Advertisement

SpringerLink
Log in

Hyperhomocyst(e)inemia

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion Statement

Hyperhomocyst(e)inemia is under scrutiny as a novel risk factor for atherosclerotic disease in the coronary, cerebral, and peripheral arterial circulations. It also appears to be a risk factor for venous thromboembolism. Low dietary intake of vitamins B6 and folic acid is the most prevalent cause of hyperhomocyst(e)inemia. A critical unresolved question is whether hyperhomocyst(e)inemia itself, or alternatively some other effect of low vitamin levels, is the true determinant of excess cardiovascular risk. This issue is currently being addressed by prospective epidemiologic studies. There is also an urgent need for prospective randomized studies to determine whether vitamin supplementation is beneficial in the primary or secondary prophylaxis of atherosclerotic disease. In the meantime, lifestyle modifications and vitamin supplementation to reduce plasma homocysteine levels can be recommended, because these are innocuous interventions that may well prove to be beneficial. Until there is definitive evidence that treatment of hyperhomocyst(e)inemia does in fact alter clinical outcomes, however, other therapies that possess the potential for greater toxicity cannot be justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rasmussen K, Moller J, Lyngbak M, et al.: Age- and gender-specific reference ranges for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996, 42:630–636.

    PubMed  CAS  Google Scholar 

  2. Selhub J, Jacques PF, Wilson PFW, et al.: Vitamin status and intake as primary determinants of hyperhomocysteinemia in elderly patients. JAMA 1993, 270:2693–2698.

    Article  PubMed  CAS  Google Scholar 

  3. Guttormsen AB, Ueland PM, Nesthus I, et al.: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 mmol/L). The Hordaland Homocysteine Study. J Clin Invest 1996, 98:2174–2183.

    PubMed  CAS  Google Scholar 

  4. Nygard O, Refsum H, Ueland PM, et al.: Coffee consumption and plasma total homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr 1997, 65:136–143.

    PubMed  CAS  Google Scholar 

  5. Nygard O, Vollset SE, Refsum H, et al.: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995, 275:1526–1533.

    Article  Google Scholar 

  6. Graham IM, Daly LE, Refsum HM, et al.: Plasma homocysteine as a risk for vascular disease. The European Concerted Action Project. JAMA 1997, 277:1775–1781.

    Article  PubMed  CAS  Google Scholar 

  7. Bostom AG, Jacques PF, Nadeau MR, et al.: Postmethionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995, 116:147–151.

    Article  PubMed  CAS  Google Scholar 

  8. Boers GHJ, Smals AG, Trijbels FJ, et al.: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial vascular disease. N Engl J Med 1985, 313:709–715.

    Article  PubMed  CAS  Google Scholar 

  9. Clarke R, Daly L, Robinson K, et al.: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991, 324:1149–1155.

    Article  PubMed  CAS  Google Scholar 

  10. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049–1057. A meta-analysis of case-control studies performed up to 1995. This article 1) suggested that 10% of the population’s risk of development of coronary artery disease is attributable to total homocysteine level and 2) urged dietary supplementation with folate.

    Article  PubMed  CAS  Google Scholar 

  11. Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877–881.

    Article  PubMed  CAS  Google Scholar 

  12. Arnesen E, Refsum H, Bonaa KH, et al.: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995, 24:877–881.

    Article  Google Scholar 

  13. Chasan-Taber L, Selhub J, Rosenberg IH, et al.: A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996, 15:136–143.

    PubMed  CAS  Google Scholar 

  14. Folsom AR, Nieto J, McGovern PG, et al.: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998, 98:204–210.

    PubMed  CAS  Google Scholar 

  15. Evans RW, Shaten BJ, Hempel JD, et al. for the MRFIT Research Group: Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscl Thromb Vasc Biol 1997, 17:1947–1953.

    PubMed  CAS  Google Scholar 

  16. Verhoef P, Stampfer MJ, Buring JE, et al.: Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996, 143:845–859.

    PubMed  CAS  Google Scholar 

  17. Morrison HI, Schaubel D, Desmueles M, Wigle DT: Serum folate and risk of fatal coronary heart disease. JAMA 1996, 275:1893–1896.

    Article  PubMed  CAS  Google Scholar 

  18. Rimm EB, Willett WC, Hu FB, et al.: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359–364. The first large study to suggest that folate and B6 supplementation may be important in the primary prevention of coronary artery disease.

    Article  PubMed  CAS  Google Scholar 

  19. Kuller LH, Evans RW: Homocysteine, vitamins, and cardiovascular disease. Circulation 1998, 98:196–199.

    PubMed  CAS  Google Scholar 

  20. Malinow MR, Duell PB, Hess DL, et al.: Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998, 338:1009–1015.

    Article  PubMed  CAS  Google Scholar 

  21. Mudd SH, Skovby F, Levy HL, et al.: The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985, 37:1–31.

    PubMed  CAS  Google Scholar 

  22. Peterson JC, Spence JD: Vitamins and progression of atherosclerosis in hyper-homocyst(e)inemia [letter]. Lancet 1998, 351:263.

    Article  PubMed  CAS  Google Scholar 

  23. Nygard O, Nordrehaug JE, Refsum H, et al.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230–236. A provocative study that suggested that plasma total homocysteine level is a strong predictor of death in patients with coronary artery disease.

    Article  PubMed  CAS  Google Scholar 

  24. Bostom AG, Shemin D, Lapane KL, et al.: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147–152.

    Article  PubMed  CAS  Google Scholar 

  25. Bostom AG, Shemin D, Nadeau MR, et al.: Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995, 113:129–132.

    Article  PubMed  CAS  Google Scholar 

  26. Homocysteine Lowering Trialists’ Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998, 316:894–898. A meta-analysis of 12 published studies containing more than 1100 patients to determine the amount of reduction of (baseline) homocysteine concentration produced by folic acid, B6, and B12 supplements.

    Google Scholar 

  27. Van den Berg M, Boers GHJ: Homocystinuria: what about mild hyperhomocysteinemia? BMJ 1996, 72:513–518.

    Google Scholar 

  28. Brattstrom L: Vitamins as homocysteine-lowering agents. J Nutr 1996, 126:1276S-1280S.

    PubMed  CAS  Google Scholar 

  29. Ubbink JB, van der Merwe A, Delport R, et al.: The effect of subnormal vitamin B6 status on homocysteine metabolism. J Clin Invest 1996, 98:177–184.

    PubMed  CAS  Google Scholar 

  30. Anker G, Lonning PE, Ueland PM, et al.: Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Cancer 1995, 60:365–368.

    CAS  Google Scholar 

  31. Van der Mooren MJ, Wouters MGAJ, Blom HJ, et al.: Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994, 24:733–736.

    Article  PubMed  Google Scholar 

  32. Refsum H, Ueland PM: Clinical significance of pharmacological modulation of homocysteine metabolism. Trends Pharmacol Sci 1990, 11:411–416.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Minnesota Medical School and Minnesota Vascular Diseases Center, Box 480 Mayo, Harvard St. at East River Road, 55455, Minneapolis, MN, USA

    Nigel S. Key MB, FRCP

Authors
  1. Nigel S. Key MB, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Key, N.S. Hyperhomocyst(e)inemia. Curr Treat Options Cardio Med 2, 65–72 (2000). https://doi.org/10.1007/s11936-000-0029-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-000-0029-7

Keywords

Search

Navigation